B of A Securities Maintains Buy on Sana Biotechnology, Lowers Price Target to $6
B of A Securities analyst Alex Stranahan maintains Sana Biotechnology (NASDAQ:SANA) with a Buy and lowers the price target from $7 to $6.
Read original at benzingaStocks · News reference
Sana Biotechnolog Publishes Peer-Reviewed Letter To Editor In New England Journal Of Medicine
Peer-Reviewed Letter to the Editor Describes Updated Long-Term Findings Consistent with Initial Trial Data Featured in NEJM Article Published in 2025Seminal Study Successfully Achieved Primary and Secondary Endpoints,
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 13, 2026, 12:03 PM
- Checked
- Jul 13, 2026, 12:03 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Sana Biotechnology Q2 Adj. EPS $(0.13) Beats $(0.15) Estimate
Sana Biotechnology (NASDAQ:SANA) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.15) by 13.33 percent. This is a 18.75 percent increase over losses of $(0.16) per share
Read original at benzinga8-K filing — Sana Biotechnology, Inc. (SANA)
Filed: 2026-08-10 AccNo: 0001193125-26-342371 Size: 541 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgar